NZ624063A - Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors - Google Patents
Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitorsInfo
- Publication number
- NZ624063A NZ624063A NZ624063A NZ62406311A NZ624063A NZ 624063 A NZ624063 A NZ 624063A NZ 624063 A NZ624063 A NZ 624063A NZ 62406311 A NZ62406311 A NZ 62406311A NZ 624063 A NZ624063 A NZ 624063A
- Authority
- NZ
- New Zealand
- Prior art keywords
- penta
- parp inhibitors
- compounds
- cyclic
- fused tetra
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085148 WO2013097225A1 (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ624063A true NZ624063A (en) | 2016-09-30 |
Family
ID=48696280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ624063A NZ624063A (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US9260440B2 (OSRAM) |
| EP (2) | EP3315500B1 (OSRAM) |
| JP (1) | JP6034877B2 (OSRAM) |
| KR (1) | KR101716012B1 (OSRAM) |
| CN (2) | CN103703004B (OSRAM) |
| AU (1) | AU2011384858B2 (OSRAM) |
| BR (1) | BR112014012628B8 (OSRAM) |
| CA (1) | CA2856309C (OSRAM) |
| CY (1) | CY1119804T1 (OSRAM) |
| DK (1) | DK2797921T3 (OSRAM) |
| EA (1) | EA027533B1 (OSRAM) |
| ES (1) | ES2645814T3 (OSRAM) |
| HR (1) | HRP20171883T1 (OSRAM) |
| HU (1) | HUE035153T2 (OSRAM) |
| IL (1) | IL233365A (OSRAM) |
| IN (1) | IN2014DN06169A (OSRAM) |
| LT (1) | LT2797921T (OSRAM) |
| ME (1) | ME02855B (OSRAM) |
| MX (1) | MX353578B (OSRAM) |
| NO (1) | NO2797921T3 (OSRAM) |
| NZ (1) | NZ624063A (OSRAM) |
| PL (1) | PL2797921T3 (OSRAM) |
| PT (1) | PT2797921T (OSRAM) |
| RS (1) | RS56616B1 (OSRAM) |
| SG (1) | SG11201401726VA (OSRAM) |
| SI (1) | SI2797921T1 (OSRAM) |
| SM (1) | SMT201700543T1 (OSRAM) |
| WO (1) | WO2013097225A1 (OSRAM) |
| ZA (1) | ZA201405560B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3315500B1 (en) | 2011-12-31 | 2020-03-18 | BeiGene, Ltd. | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| KR102104144B1 (ko) | 2012-03-07 | 2020-04-23 | 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 | 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 |
| CN105722835B (zh) | 2013-09-11 | 2018-07-31 | 癌症研究协会:皇家癌症医院 | 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用 |
| BR112018003634B1 (pt) * | 2015-08-25 | 2023-11-21 | Beigene Switzerland Gmbh | Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma |
| SG11201807708SA (en) | 2016-04-01 | 2018-10-30 | Zeno Royalties & Milestones Llc | Estrogen receptor modulators |
| EP3519051B1 (en) * | 2016-09-27 | 2021-09-22 | Beigene, Ltd. | Treatment of cancers using combination comprising parp inhibitors |
| CN110392687B (zh) * | 2017-02-28 | 2022-08-02 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途 |
| CN106883232B (zh) | 2017-03-31 | 2019-01-22 | 苏州康润医药有限公司 | 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用 |
| AU2018302999A1 (en) * | 2017-07-17 | 2020-01-30 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy |
| CN112292133A (zh) * | 2018-06-01 | 2021-01-29 | 百济神州有限公司 | 在胃癌治疗中的parp抑制剂维持疗法 |
| CN111171031B (zh) * | 2019-05-10 | 2021-04-09 | 百济神州(苏州)生物科技有限公司 | 一种含parp抑制剂倍半水合物产物的制备方法 |
| CN111171002B (zh) * | 2019-05-16 | 2021-04-06 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的制备方法 |
| MX2021014339A (es) * | 2019-05-31 | 2022-01-06 | Beigene Ltd | Preparacion de granulo inhibidor de parp y proceso de preparacion del mismo. |
| MX2022001149A (es) | 2019-08-06 | 2022-04-06 | Recurium Ip Holdings Llc | Moduladores del receptor de estrógeno para el tratamiento de mutantes. |
| WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE445326B (sv) | 1983-04-05 | 1986-06-16 | Malmstroem Anders E H | Sett och anordning for forhindrande av veggturbulens |
| US6799298B2 (en) | 1998-03-11 | 2004-09-28 | Overture Services, Inc. | Technique for locating an item of interest within a stored representation of data |
| ATE261963T1 (de) | 1999-01-11 | 2004-04-15 | Agouron Pharma | Tricyclische inhibitoren von poly(adp-ribose) polymerasen |
| EP1339402B1 (en) | 2000-12-01 | 2010-08-25 | Eisai Inc. | Azaphenanthridone derivatives and their use as parp inhibitors |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| US6906096B2 (en) | 2002-06-28 | 2005-06-14 | Irm Llc | 4,7-Disubstituted indoles and methods of making |
| DK1585749T3 (da) * | 2003-01-09 | 2008-09-22 | Pfizer | Diazepinoindol-derivater som kinaseinhibitorer |
| ES2396334T3 (es) | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
| EP2004655A1 (en) | 2006-04-04 | 2008-12-24 | Pfizer Products Incorporated | Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide |
| MX2008012791A (es) | 2006-04-04 | 2008-10-15 | Pfizer Prod Inc | Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-meti l-1h-pirazol-4-il)-1-oxo-2,6-dihidro-1h-[1,2]diazepinos[4,5,6-cd[ indol-8-il)acetamida. |
| WO2009063244A1 (en) | 2007-11-15 | 2009-05-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Pyridazinone derivatives as parp inhibitors |
| WO2010017055A2 (en) * | 2008-08-06 | 2010-02-11 | Lead Therapeutics, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| EP3315500B1 (en) | 2011-12-31 | 2020-03-18 | BeiGene, Ltd. | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| US10544225B2 (en) | 2014-07-03 | 2020-01-28 | Beigene, Ltd. | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| BR112018003634B1 (pt) | 2015-08-25 | 2023-11-21 | Beigene Switzerland Gmbh | Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma |
| EP3519051B1 (en) | 2016-09-27 | 2021-09-22 | Beigene, Ltd. | Treatment of cancers using combination comprising parp inhibitors |
| CN110392687B (zh) | 2017-02-28 | 2022-08-02 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途 |
| AU2018302999A1 (en) | 2017-07-17 | 2020-01-30 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy |
-
2011
- 2011-12-31 EP EP17183473.2A patent/EP3315500B1/en active Active
- 2011-12-31 PL PL11878508T patent/PL2797921T3/pl unknown
- 2011-12-31 BR BR112014012628A patent/BR112014012628B8/pt not_active IP Right Cessation
- 2011-12-31 KR KR1020147018104A patent/KR101716012B1/ko active Active
- 2011-12-31 WO PCT/CN2011/085148 patent/WO2013097225A1/en not_active Ceased
- 2011-12-31 CN CN201180072418.8A patent/CN103703004B/zh active Active
- 2011-12-31 CN CN201610603192.4A patent/CN106220635B/zh active Active
- 2011-12-31 HR HRP20171883TT patent/HRP20171883T1/hr unknown
- 2011-12-31 NZ NZ624063A patent/NZ624063A/en not_active IP Right Cessation
- 2011-12-31 JP JP2014549295A patent/JP6034877B2/ja not_active Expired - Fee Related
- 2011-12-31 SG SG11201401726VA patent/SG11201401726VA/en unknown
- 2011-12-31 PT PT118785088T patent/PT2797921T/pt unknown
- 2011-12-31 AU AU2011384858A patent/AU2011384858B2/en not_active Ceased
- 2011-12-31 EA EA201491303A patent/EA027533B1/ru not_active IP Right Cessation
- 2011-12-31 ME MEP-2017-278A patent/ME02855B/me unknown
- 2011-12-31 HU HUE11878508A patent/HUE035153T2/en unknown
- 2011-12-31 MX MX2014007840A patent/MX353578B/es active IP Right Grant
- 2011-12-31 SI SI201131351T patent/SI2797921T1/en unknown
- 2011-12-31 US US14/369,374 patent/US9260440B2/en active Active
- 2011-12-31 ES ES11878508.8T patent/ES2645814T3/es active Active
- 2011-12-31 DK DK11878508.8T patent/DK2797921T3/en active
- 2011-12-31 RS RS20171228A patent/RS56616B1/sr unknown
- 2011-12-31 EP EP11878508.8A patent/EP2797921B1/en active Active
- 2011-12-31 NO NO11878508A patent/NO2797921T3/no unknown
- 2011-12-31 IN IN6169DEN2014 patent/IN2014DN06169A/en unknown
- 2011-12-31 CA CA2856309A patent/CA2856309C/en active Active
- 2011-12-31 LT LTEP11878508.8T patent/LT2797921T/lt unknown
- 2011-12-31 SM SM20170543T patent/SMT201700543T1/it unknown
-
2014
- 2014-06-25 IL IL233365A patent/IL233365A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05560A patent/ZA201405560B/en unknown
-
2016
- 2016-01-05 US US14/988,484 patent/US9617273B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 US US15/479,958 patent/US10112952B2/en active Active
- 2017-11-16 CY CY20171101198T patent/CY1119804T1/el unknown
-
2018
- 2018-09-19 US US16/135,512 patent/US10501467B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ624063A (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
| NZ626937A (en) | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors | |
| IN2014DN07384A (OSRAM) | ||
| WO2013077921A3 (en) | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| AU2013328732A8 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| SMT202300157T1 (it) | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro | |
| PH12013501758A1 (en) | Pyrazolo [1,5-a] pyridines as trk inhibitors | |
| MX378957B (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa | |
| IL235659A (en) | History 3, 4 - Dihydro-h2 - Pyrido [1, 2 - a] Pyrazine – 1, 6 - Transformed deion used to treat (among other things) Alzheimer's disease | |
| AU2012313399A8 (en) | 8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8H) -ones for the treatment of nervous system disorders and cancer | |
| NZ600430A (en) | Spiro-oxindole mdm2 antagonists | |
| MY172308A (en) | Bicyclic pyrazinone derivatives | |
| WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
| TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
| WO2015095337A3 (en) | PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT | |
| MD20150023A2 (ro) | Piridinone biciclice noi | |
| MX357502B (es) | Derivados de pirrolotriazinona. | |
| WO2014045162A8 (en) | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS | |
| MX2011013870A (es) | Compuestos biciclicos y triciclicos como inhibidores de quinurenina aminotransferasa ii. | |
| CL2014000641A1 (es) | Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras. | |
| AU2013218357A8 (en) | Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors | |
| IN2014DN09826A (OSRAM) | ||
| WO2011094434A3 (en) | 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof | |
| NZ609924A (en) | Porphyrin treatment of neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 DEC 2018 BY GRIFFITH HACK Effective date: 20170110 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2019 BY ACUMASS Effective date: 20181119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2020 BY ACUMASS Effective date: 20191120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2021 BY ACUMASS Effective date: 20201118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2022 BY ACUMASS Effective date: 20211122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2023 BY ACUMASS Effective date: 20221118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2024 BY ACUMASS Effective date: 20231121 |
|
| LAPS | Patent lapsed |